Keywords: GlaxoSmithKline, Financial results, Second-quarter 2012
GlaxoSmithKline blames harsh pharma "environment" for 2nd-qtr sales and EPS decline
Article | 26 July 2012
UK pharma giant GlaxoSmithKline (LSE: GSK) posted a downturn in second-quarter 2012 turnover, which fell 4% (-2% at constant exchange rates) to & ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
